Azitra, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Azitra, Inc. (AZTR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $0.00.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $0.87, a 85.28% decline from fiscal 2022.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $5.91.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.87 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $0.87 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.93 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $5.91 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |